Abstract
The enzyme xanthine oxidoreductase (XOR) catalyzes the last two steps of purine catabolism in the highest uricotelic primates. XOR is an enzyme with dehydrogenase activity that, in mammals, may be converted into oxidase activity under a variety of pathophysiologic conditions. XOR activity is highly regulated at the transcriptional and post-translational levels and may generate reactive oxygen and nitrogen species, which trigger different consequences, ranging from cytotoxicity to inflammation. The low specificity for substrates allows XOR to metabolize a number of endogenous metabolites and a variety of exogenous compounds, including drugs.
The present review focuses on the role of XOR as a drug-metabolizing enzyme, specifically for drugs with anticancer, antimicrobial, antiviral, immunosuppressive or vasodilator activities, as well as drugs acting on metabolism or inducing XOR expression.
XOR has an activating role that is essential to the pharmacological action of quinone drugs, cyadox, antiviral nucleoside analogues, allopurinol, nitrate and nitrite. XOR activity has a degradation function toward thiopurine nucleotides, pyrazinoic acid, methylxanthines and tolbutamide, whose half-life may be prolonged by the use of XOR inhibitors.
In conclusion, to avoid potential drug interaction risks, such as a toxic excess of drug bioavailability or a loss of drug efficacy, caution is suggested in the use of XOR inhibitors, as in the case of hyperuricemic patients affected by gout or tumor lysis syndrome, when it is necessary to simultaneously administer therapeutic substances that are activated or degraded by the drug-metabolizing activity of XOR.
Keywords: Anticancer drugs, Antimicrobial drugs, Immunosuppressive drugs, Nitrovasodilators, Purine analogues, Xanthine oxidoreductase.
Current Medicinal Chemistry
Title:Xanthine Oxidoreductase in Drug Metabolism: Beyond a Role as a Detoxifying Enzyme
Volume: 23 Issue: 35
Author(s): Maria Giulia Battelli, Letizia Polito, Massimo Bortolotti and Andrea Bolognesi
Affiliation:
Keywords: Anticancer drugs, Antimicrobial drugs, Immunosuppressive drugs, Nitrovasodilators, Purine analogues, Xanthine oxidoreductase.
Abstract: The enzyme xanthine oxidoreductase (XOR) catalyzes the last two steps of purine catabolism in the highest uricotelic primates. XOR is an enzyme with dehydrogenase activity that, in mammals, may be converted into oxidase activity under a variety of pathophysiologic conditions. XOR activity is highly regulated at the transcriptional and post-translational levels and may generate reactive oxygen and nitrogen species, which trigger different consequences, ranging from cytotoxicity to inflammation. The low specificity for substrates allows XOR to metabolize a number of endogenous metabolites and a variety of exogenous compounds, including drugs.
The present review focuses on the role of XOR as a drug-metabolizing enzyme, specifically for drugs with anticancer, antimicrobial, antiviral, immunosuppressive or vasodilator activities, as well as drugs acting on metabolism or inducing XOR expression.
XOR has an activating role that is essential to the pharmacological action of quinone drugs, cyadox, antiviral nucleoside analogues, allopurinol, nitrate and nitrite. XOR activity has a degradation function toward thiopurine nucleotides, pyrazinoic acid, methylxanthines and tolbutamide, whose half-life may be prolonged by the use of XOR inhibitors.
In conclusion, to avoid potential drug interaction risks, such as a toxic excess of drug bioavailability or a loss of drug efficacy, caution is suggested in the use of XOR inhibitors, as in the case of hyperuricemic patients affected by gout or tumor lysis syndrome, when it is necessary to simultaneously administer therapeutic substances that are activated or degraded by the drug-metabolizing activity of XOR.
Export Options
About this article
Cite this article as:
Battelli Giulia Maria, Polito Letizia, Bortolotti Massimo and Bolognesi Andrea, Xanthine Oxidoreductase in Drug Metabolism: Beyond a Role as a Detoxifying Enzyme, Current Medicinal Chemistry 2016; 23 (35) . https://dx.doi.org/10.2174/0929867323666160725091915
DOI https://dx.doi.org/10.2174/0929867323666160725091915 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ACE and ACE2 in Inflammation: A Tale of Two Enzymes
Inflammation & Allergy - Drug Targets (Discontinued) Neuroprotective Effects of Heat Shock Protein70
CNS & Neurological Disorders - Drug Targets Neuroprotection and Behavior Regulation by Adrenomedullin and PAMP as Shown by Conditional Knockout Models
Current Hypertension Reviews Antiplatelet Therapy in the Prevention of Coronary Syndromes: Mode of Action, Benefits, Drawbacks
Cardiovascular & Hematological Agents in Medicinal Chemistry Strategic Leukofiltration in Cardiac Surgery
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Protective Effects of Astragalus Membranaceus and Ligustrazine on Rat Brain Microvascular Endothelial Cell Injury after Oxygen-Glucose Deprivation/ Reoxygenation by Suppressing the PKCδ/MARCKS Pathway
Combinatorial Chemistry & High Throughput Screening The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Cell Cycle Arrest as a Therapeutic Target of Acute Kidney Injury
Current Protein & Peptide Science Recent Advances and Patents on Coronary Sinus Perfusion Devices for Treatment of Heart Disease
Recent Patents on Biomedical Engineering (Discontinued) Ototoxicity: Mechanisms of Cochlear Impairment and its Prevention
Current Medicinal Chemistry ADAM10 as a Therapeutic Target for Cancer and Inflammation
Current Pharmaceutical Design Recent Advances in the Discovery of Tissue Factor/Factor VIIa Inhibitors and Dual Inhibitors of Factor VIIa/Factor Xa
Current Pharmaceutical Design Approaches to Target Profiling of Natural Products
Current Medicinal Chemistry Intracranial Aneurysms in Sickle Cell Disease
Current Neurovascular Research Scaffold Hopping for Identification of Novel PKCβII Inhibitors Based on Ligand and Structural Approaches, Virtual Screening and Molecular Dynamics Study
Combinatorial Chemistry & High Throughput Screening Subject Index To Volume 2
Current Cardiology Reviews Role of Peroxynitrite in the Cardiovascular Dysfunction of Septic Shock
Current Vascular Pharmacology Morphofunctional Aspects of the Blood-Brain Barrier
Current Drug Metabolism Anti-Inflammatory, Gastrointestinal and Hepatoprotective Effects of Ocimum sanctum Linn: An Ancient Remedy with New Application
Inflammation & Allergy - Drug Targets (Discontinued) Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews